E-cadherin expression in plasmacytoid, signet ring cell and micropapillary variants of urothelial carcinoma: Comparison with usual-type high-grade urothelial carcinoma

Modern Pathology

Volumn 24, Issue 2, 2011, Pages 241-247

  Lim, Matthew G ^a   Adsay, N Volkan ^a,b   Grignon, David J ^c   Osunkoya, Adeboye O ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

E cadherin; expression; urothelial carcinoma

Indexed keywords

TUMOR MARKER; UVOMORULIN;

ARTICLE; CANCER GRADING; CANCER INVASION; CANCER STAGING; CELL DIFFERENTIATION; CYSTECTOMY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; LAMINA PROPRIA; LYMPHATIC SYSTEM; PHENOTYPE; PRIORITY JOURNAL; PROSTATECTOMY; PROTEIN EXPRESSION; SIGNET RING CARCINOMA; URINARY TRACT CARCINOMA;

CADHERINS; CARCINOMA, PAPILLARY; CARCINOMA, SIGNET RING CELL; CARCINOMA, TRANSITIONAL CELL; DENDRITIC CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM STAGING; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 79551624265     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.187     Document Type: Article

References (64)

1. Takeichi M. The cadherins: cell-cell adhesion molecules controlling animal morphogenesis. Development 1988;102:639-655.
2. Shirayoshi Y, Okada TS, Takeichi M. The calciumdependent cell-cell adhesion system regulates inner cell mass formation and cell surface polarization in early mouse development. Cell 1983;35:631-638.
3. Otto T, BirchmeierW, Schmidt U, et al. Inverse relation of E-cadherin and autocrine motility factor receptor expression as a prognostic factor in patients with bladder carcinomas. Cancer Res 1994;54:3120-3123.
4. Rieger-Christ KM, Cain JW, Braasch JW, et al. Expression of classic cadherins type I in urothelial neoplastic progression. Hum Pathol 2001;32:18-23.
5. Oka H, Shiozaki H, Kobayashi K, et al. Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res 1993;53:1696-1701.
6. Schipper JH, Frixen UH, Behrens J, et al. E-cadherin expression in squamous cell carcinomas of head and neck: inverse correlation with tumor dedifferentiation and lymph node metastasis. Cancer Res 1991;51: 6328-6337.
7. Umbas R, Schalken JA, Aalders TW, et al. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 1992;52:5104-5109.
8. Bringuier PP, Umbas R, Schaafsma HE, et al. Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res 1993;53:3241-3245.
9. Kawakita M, Moroi S, Kyotani K, et al. Study on E-cadherin expression in relation to invasion and metastasis in urothelial cancer patients. Hinyokika Kiyo 1994;40:1077-1080.
10. Miyazaki J, Fujisawa M, Arakawa S, et al. The expression of the E-cadherin in human urinary bladder carcinoma. Nippon Hinyokika Gakkai Zasshi 1995;86: 1208-1215.
11. Cai T, Piazzini M, Nesi G, et al. E-cadherin mRNA expression analysis in evaluating the natural history of urothelial bladder cell carcinoma: results from a longterm followup study. Oncol Rep 2007;17:925-930.
12. Erdemir F, Ozcan F, Kilicaslan I, et al. The relationship between the expression of Ecadherin and tumor recurrence and progression in high-grade stage T1 bladder urothelial carcinoma. Int Urol Nephrol 2007; 39:1031-1037.
13. Sun W, Herrera GA. E-cadherin expression in urothelial carcinoma in situ, superficial papillary transitional cell carcinoma, and invasive transitional cell carcinoma. Hum Pathol 2002;33:996-1000.
14. Tsukino H, Kuroda Y, Nakao H, et al. E-cadherin gene polymorphism and risk of urothelial cancer. Cancer Lett 2003;195:53-58. (Pubitemid 36588978)
15. Sun W, Herrera GA. E-cadherin expression in invasive urothelial carcinoma. Ann Diagn Pathol 2004;8:17-22.
16. Okegawa T, Li Y, Pong RC, et al. Cell adhesion proteins as tumor suppressors. J Urol 2002;167:1836-1843.
17. McConkey DJ, Choi W, Marquis L, et al. Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev 2009;28:335-344.
18. Fujisawa M, Miyazaki J, Takechi Y, et al. The significance of Ecadherin in transitional-cell carcinoma of the human urinary bladder. World J Urol 1996;14(Suppl 1):S12-S15.
19. Lopez-Beltran A, Cheng L. Histologic variants of urothelial carcinoma: differential diagnosis and clinical implications. Hum Pathol 2006;37:1371-1388.
20. Lopez-Beltran A, Requena MJ, Cheng L, et al. Pathological variants of invasive bladder cancer according to their suggested clinical significance. BJU Int 2008; 101:275-281.
21. Lopez-Beltran A, Requena MJ, Montironi R, et al. Plasmacytoid urothelial carcinoma of the bladder. Hum Pathol 2009;40:1023-1028.
22. Nigwekar P, Tamboli P, Amin MB, et al. Plasmacytoid urothelial carcinoma: detailed analysis of morphology with clinicopathologic correlation in 17 cases. Am J Surg Pathol 2009;33:417-424.
23. Ro JY, Shen SS, Lee HI, et al. Plasmacytoid transitional cell carcinoma of urinary bladder: a clinicopathologic study of 9 cases. Am J Surg Pathol 2008;32:752-757.
24. Amin MB, Ro JY, El-Sharkawy T, et al. Micropapillary variant of transitional cell carcinoma of the urinary bladder. Histologic pattern resembling ovarian papillary serous carcinoma. Am J Surg Pathol 1994;18: 1224-1232.
25. Johansson SL, Borghede G, Holmang S. Micropapillary bladder carcinoma: a clinicopathological study of 20 cases. J Urol 1999;161:1798-1802.
26. Mareel M, Boterberg T, Noe V, et al. E-cadherin/ catenin/cytoskeleton complex: a regulator of cancer invasion. J Cell Physiol 1997;173:271-274.
27. Grunwald GB. The structural and functional analysis of cadherin calcium-dependent cell adhesion molecules. Curr Opin Cell Biol 1993;5:797-805.
28. Vleminckx K, Vakaet Jr L, Mareel M, et al. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 1991;66:107-119.
29. Kadowaki T, Shiozaki H, Inoue M, et al. E-cadherin and alpha-catenin expression in human esophageal cancer. Cancer Res 1994;54:291-296.
30. Kinsella AR, Lepts GC, Hill CL, et al. Reduced Ecadherin expression correlates with increased invasiveness in colorectal carcinoma cell lines. Clin Exp Metastasis 1994;12:335-342.
31. Oka H, Shiozaki H, Kobayashi K, et al. Immunohistochemical evaluation of Ecadherin adhesion molecule expression in human gastric cancer. Virchows Arch A Pathol Anat Histopathol 1992;421:149-156.
32. Doki Y, Shiozaki H, Tahara H, et al. Correlation between E-cadherin expression and invasiveness in vitro in a human esophageal cancer cell line. Cancer Res 1993;53:3421-3426.
33. Kinsella AR, Green B, Lepts GC, et al. The role of the cell-cell adhesion molecule Ecadherin in large bowel tumour cell invasion and metastasis. Br J Cancer 1993;67:904-909.
34. Matsuura K, Kawanishi J, Fujii S, et al. Altered expression of E-cadherin in gastric cancer tissues and carcinomatous fluid. Br J Cancer 1992;66:1122-1130.
35. Umbas R, Isaacs WB, Bringuier PP, et al. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 1994;54:3929-3933.
36. Byrne RR, Shariat SF, Brown R, et al. E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term follow-up. J Urol 2001;165:1473-1479.
37. Syrigos KN, Krausz T, Waxman J, et al. E-cadherin expression in bladder cancer using formalin-fixed, paraffin-embedded tissues: correlation with histopathological grade, tumour stage and survival. Int J Cancer 1995;64:367-370.
38. Shimazui T, Schalken JA, Giroldi LA, et al. Prognostic value of cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120cas) in bladder tumors. Cancer Res 1996;56:4154-4158.
39. Hong RL, Pu YS, Chu JS, et al. Correlation of expression of CD44 isoforms and Ecadherin with differentiation in human urothelial cell lines and transitional cell carcinoma. Cancer Lett 1995;89:81-87.
40. Lipponen PK, Eskelinen MJ. Reduced expression of E-cadherin is related to invasive disease and frequent recurrence in bladder cancer. J Cancer Res Clin Oncol 1995;121:303-308.
41. Mialhe A, Louis J, Montlevier S, et al. Expression of E-cadherin and alpha-, beta- and gamma-catenins in human bladder carcinomas: are they good prognostic factors? Invasion Metastasis 1997;17:124-137.
42. Chalasani V, Chin JL, Izawa JI. Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer. Can Urol Assoc J 2009;3:S193-S198.
43. Fritsche HM, Burger M, Denzinger S, et al. Plasmacytoid urothelial carcinoma of the bladder: histological and clinical features of 5 cases. J Urol 2008;180: 1923-1927.
44. Gaafar A, Garmendia M, de Miguel E, et al. Plasmacytoid urothelial carcinoma of the urinary bladder. A study of 7 cases. Actas Urol Esp 2008;32:806-810.
45. Kawashima A, Ujike T, Nin M, et al. Plasmacytoid urothelial carcinoma of the bladder: a case report. Nippon Hinyokika Gakkai Zasshi 2009;100:590-594.
46. Mai KT, Park PC, Yazdi HM, et al. Plasmacytoid urothelial carcinoma of the urinary bladder report of seven new cases. Eur Urol 2006;50:1111-1114.
47. McKenney JK, Amin MB. The role of immunohistochemistry in the diagnosis of urinary bladder neoplasms. Semin Diagn Pathol 2005;22:69-87.
48. Mitsogiannis IC, Ioannou MG, Sinani CD, et al. Plasmacytoid transitional cell carcinoma of the urinary bladder. Urology 2005;66:194.
49. Patriarca C, Di Pasquale M, Giunta P, et al. CD138- positive plasmacytoid urothelial carcinoma of the bladder. Int J Surg Pathol 2008;16:215-217.
50. Sahin AA, Myhre M, Ro JY, et al. Plasmacytoid transitional cell carcinoma. Report of a case with initial presentation mimicking multiple myeloma. Acta Cytol 1991;35:277-280.
51. Sato K, Ueda Y, Kawamura K, et al. Plasmacytoid urothelial carcinoma of the urinary bladder: a case report and immunohistochemical study. Pathol Res Pract 2009;205:189-194.
52. Shimada K, Nakamura M, Ishida E, et al. Urothelial carcinoma with plasmacytoid variants producing both human chorionic gonadotropin and carbohydrate antigen 19-9. Urology 2006;68:891 e897-810.
53. Soylu A, Aydin NE, Yilmaz U, et al. Urothelial carcinoma featuring lipid cell and plasmacytoid morphology with poor prognostic outcome. Urology 2005;65:797.
54. Zhang XM, Elhosseiny A, Melamed MR. Plasmacytoid urothelial carcinoma of the bladder. A case report and the first description of urinary cytology. Acta Cytol 2002;46:412-416.
55. Zukerberg LR, Harris NL, Young RH. Carcinomas of the urinary bladder simulating malignant lymphoma. A report of five cases. Am J Surg Pathol 1991;15:569-576.
56. Coyne JD, Sim E. Urothelial neoplasia with plasmacytoid morphology. Histopathology 2006;48:200-201.
57. Keck B, Stohr R, Goebell PJ, et al. Plasmacytoid carcinoma. Five case reports of a rare variant of urothelial carcinoma. Pathologe 2008;29:379-382.
58. Kohno T, Kitamura M, Akai H, et al. Plasmacytoid urothelial carcinoma of the bladder. Int J Urol 2006;13:485-486.
59. Lau SK. Cytomorphologic features of the plasmacytoid variant of urothelial carcinoma: a case report. Diagn Cytopathol 2009;37:359-364.
60. Shimada K, Nakamura M, Konishi N. A case of urothelial carcinoma with triple variants featuring nested, plasmacytoid, and lipoid cell morphology. Diagn Cytopathol 2009;37:272-276.
61. Grignon DJ, Ro JY, Ayala AG, et al. Primary signet-ring cell carcinoma of the urinary bladder. Am J Clin Pathol 1991;95:13-20.
62. Thomas AA, Stephenson AJ, Campbell SC, et al. Clinicopathologic features and utility of immunohistochemical markers in signet-ring cell adenocarcinoma of the bladder. Hum Pathol 2009;40:108-116.
63. Maranchie JK, Bouyounes BT, Zhang PL, et al. Clinical and pathological characteristics of micropapillary transitional cell carcinoma: a highly aggressive variant. J Urol 2000;163:748-751.
64. Lee JI. Micropapillary carcinoma of the urinary bladder: a case report. Acta Cytol 2009;53:344-348.